Spots Global Cancer Trial Database for A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Official Title: A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Study ID: NCT03414047
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with platinum-resistant or refractory recurrent ovarian cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Arizona Oncology Associates, P.C., Tucson, Arizona, United States
Kaiser Permanente Medical Center, Vallejo, California, United States
University of Southern Florida School of Medicine, Gainesville, Florida, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Research Medical Center, Kansas City, Missouri, United States
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Cancer Care Associates, Tulsa, Oklahoma, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Rhode Island Hospital, Providence, Rhode Island, United States
Sioux Valley Clinic, Sioux Falls, South Dakota, United States
University of Tennessee Medical Center, Knoxville, Tennessee, United States
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
Tennessee Oncology PLLC, Nashville, Tennessee, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Concord Repatriation General Hospital, Concord, New South Wales, Australia
Prince of Wales Hospital, Randwick, New South Wales, Australia
Westmead Hospital, Wentworthville, New South Wales, Australia
Royal Brisbane and Womens Hospital, Herston, Queensland, Australia
Mater Adult Hospital Brisbane, South Brisbane, Queensland, Australia
Flinders Medical Centre, Bedford Park, South Australia, Australia
Burnside War Memorial Hospital, Toorak Gardens, South Australia, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Institut Jules Bordet, Brussel, , Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, , Belgium
GZA St Augustinus, Wilrijk, , Belgium
Rambam Medical Center, Haifa, , Israel
Shaare Zedek Medical Center, Jerusalem, , Israel
Sheba Medical Center, Ramat Gan, , Israel
Policlinico Univ. Agostino Gemelli, Roma, Lazio, Italy
Istituto Europeo di Oncologia, Milano, Milan, Italy
Istituto Tumori Fondazione G. Pascale IRCCS, Napoli, Naples, Italy
Samsung Medical Center, Seoul, Korea, Korea, Republic of
Seoul National University Hospital, Seoul, , Korea, Republic of
Asan Medical Center, Seoul, , Korea, Republic of
Severance Hospital Yonsei University Health System, Seoul, , Korea, Republic of
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
Hospital Reina Sofia, Cordoba, , Spain
Hospital Universitario Ramon y Cajal, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital Universitario La Paz, Madrid, , Spain
University College Hospital - London, London, Greater London, United Kingdom
Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Northampton General Hospital, Northampton, , United Kingdom
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
